General
Preferred name
REBAMIPIDE
Synonyms
Opc 12759 ()
Proamipide ()
OPC12759 ()
Mucosta ()
rebamipide (ophthalmic) ()
OPC-12759,Proamipide ()
Rebator ()
NSC-758955 ()
Rebamipida ()
OPC-12759 ()
Rebamipide-d4 ()
P&D ID
PD000950
CAS
111911-87-6
90098-04-7
1219409-06-9
Tags
available
drug
Approved by
PMDA
First approval
2011
Drug indication
dry eye syndrome
Peptic ulcer
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Rebamipide is an amino acid derivative of 2-(1H)-quinolinone with gastroprotective action .
(GtoPdb)
PRICE
29
DESCRIPTION
Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer[1][2].
DESCRIPTION
Rebamipide is a gastroprotective agent used in combination with other similar therapies to treat gastritis and protect the gastric mucosa.
(Enamine Bioactive Compounds)
DESCRIPTION
Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Enamine Bioactive Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Molecular Weight
370.07
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.61
TPSA
99.26
Fraction CSP3
0.11
Chiral centers
1.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
COX
Free radical scavengers
Prostaglandin Receptor
CCK Receptor
Biosynthetic Origin
Other (Amino Acid)
Therapeutic Indication
Antiulcer
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
oxidation-reduction
Source data
